미르베툭시맙 소라브탄신(IMGN853)은 엽산수용체 알파(FRa) 결합 항체, 분열 가능한 링커 및 표적 암세포를 사멸시키는 강력한 튜프린 표적 약물인 메이탄시노이드 페이로드 DM4로 구성된 최초의 ADC입니다. 밀베툭시맙솔라부탄신의 항 FOLR1 단일클론 항체 부분은 세포 표면 항원 FOLR1을 표적으로 결합합니다. 항체와 항원이 상호 작용하여 내재화되면 면역복합체는 DM4를 방출하고, DM4는 튜브린에 결합하여 미세소관 집합/분해 동역학을 억제하여 FOLR1을 발현하는 종양세포의 세포분열과 세포증식을 억제합니다. 엽산 수용체 계열의 일원인 FOLR1은 다양한 상피 유래 암세포에서 과발현됩니다. 설포-SPDB 링커는 혈류에서 절단되는 것을 방지하여 다제내성 종양세포에 대한 약물의 효능을 향상시킬 수 있습니다. 백금제제 민감성 난소암의 후기 치료제로서, 그리고 백금제제 내성 및 백금제제 민감성 질환에 대한 병용요법으로 연구되고 있습니다.
앞으로 몇 년동안 난소암 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 미르베툭시맙 소라브탄신의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 난소암에 대한 다른 신흥 제품들이 미르베툭시맙 소라브탄신과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 난소암 치료제 미르베툭시맙 소라브탄신(Milbetuximab Sorabtancin) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.
목차
제1장 보고서 서론
제2장 난소암 치료제 미르베툭시맙 소라브탄신 개요
- 제품 상세
- 임상 개발
- 규제 마일스톤
- 기타 개발 활동
- 제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신흥 치료법)
제5장 미르베툭시맙 소라브탄신 시장 평가
- 난소암 치료제 미르베툭시맙 소라브탄신 시장 전망
- 주요 7개국 분석
- 주요 7개국의 난소암 치료제 미르베툭시맙 소라브탄신 시장 규모
- 국가별 시장 분석
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight에 대해
제12장 보고서 구입 옵션
LSH
"Mirvetuximab Soravtansine Market Size, Forecast, and Drug Insight - 2032" report provides comprehensive insights about mirvetuximab soravtansine for ovarian cancer in the seven major markets. A detailed picture of the mirvetuximab soravtansine for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mirvetuximab soravtansine for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mirvetuximab soravtansine market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
Drug Summary:
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRa)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family, is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug-resistant tumor cells. It is being studied in later line platinum-sensitive ovarian cancer and in combination in both platinum-resistant and platinum-sensitive diseases.
Scope of the Report:
The report provides insights into:
- A comprehensive product overview including the mirvetuximab soravtansine description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
- Elaborated details on mirvetuximab soravtansine regulatory milestones and other development activities have been provided in this report.
- The report also highlights the mirvetuximab soravtansine research and development activities in ovarian cancer across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around mirvetuximab soravtansine.
- The report contains forecasted sales of mirvetuximab soravtansine for ovarian cancer till 2032.
- Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
- The report also features the SWOT analysis with analyst views for mirvetuximab soravtansine in ovarian cancer.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Mirvetuximab Soravtansine Analytical Perspective by DelveInsight
- In-depth Mirvetuximab Soravtansine Market Assessment
This report provides a detailed market assessment of mirvetuximab soravtansine for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
- Mirvetuximab Soravtansine Clinical Assessment
The report provides the clinical trials information of mirvetuximab soravtansine for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
- In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mirvetuximab soravtansine dominance.
- Other emerging products for ovarian cancer are expected to give tough market competition to mirvetuximab soravtansine and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mirvetuximab soravtansine in ovarian cancer.
- Our in-depth analysis of the forecasted sales data of mirvetuximab soravtansine from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mirvetuximab soravtansine in ovarian cancer.
Key Questions:
- What is the product type, route of administration and mechanism of action of mirvetuximab soravtansine?
- What is the clinical trial status of the study related to mirvetuximab soravtansine in ovarian cancer and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mirvetuximab soravtansine development?
- What are the key designations that have been granted to mirvetuximab soravtansine for ovarian cancer?
- What is the forecasted market scenario of mirvetuximab soravtansine for ovarian cancer?
- What are the forecasted sales of mirvetuximab soravtansine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to mirvetuximab soravtansine for ovarian cancer?
- Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?
Table of Contents
1. Report Introduction
2. Mirvetuximab soravtansine Overview in ovarian cancer
- 2.1. Product Detail
- 2.2. Clinical Development
- 2.2.1. Clinical studies
- 2.2.2. Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Regulatory Milestones
- 2.4. Other Developmental Activities
- 2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. Mirvetuximab soravtansine Market Assessment
- 5.1. Market Outlook of Mirvetuximab soravtansine in ovarian cancer
- 5.2. 7MM Analysis
- 5.2.1. Market Size of Mirvetuximab soravtansine in the 7MM for ovarian cancer
- 5.3. Country-wise Market Analysis
- 5.3.1. Market Size of Mirvetuximab soravtansine in the United States for ovarian cancer
- 5.3.2. Market Size of Mirvetuximab soravtansine in Germany for ovarian cancer
- 5.3.3. Market Size of Mirvetuximab soravtansine in France for ovarian cancer
- 5.3.4. Market Size of Mirvetuximab soravtansine in Italy for ovarian cancer
- 5.3.5. Market Size of Mirvetuximab soravtansine in Spain for ovarian cancer
- 5.3.6. Market Size of Mirvetuximab soravtansine in the United Kingdom for ovarian cancer
- 5.3.7. Market Size of Mirvetuximab soravtansine in Japan for ovarian cancer
6. SWOT Analysis
7. Analysts' Views
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
12. Report Purchase Options
